These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 32287402)

  • 1. Monoclonal antibodies for prophylactic and therapeutic use against viral infections.
    Both L; Banyard AC; van Dolleweerd C; Wright E; Ma JK; Fooks AR
    Pediatr Pol; 2013; 88(5):T15-T23. PubMed ID: 32287402
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Monoclonal antibodies for prophylactic and therapeutic use against viral infections.
    Both L; Banyard AC; van Dolleweerd C; Wright E; Ma JK; Fooks AR
    Vaccine; 2013 Mar; 31(12):1553-9. PubMed ID: 23370150
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Importance of Neutralizing Monoclonal Antibodies Targeting Multiple Antigenic Sites on the Middle East Respiratory Syndrome Coronavirus Spike Glycoprotein To Avoid Neutralization Escape.
    Wang L; Shi W; Chappell JD; Joyce MG; Zhang Y; Kanekiyo M; Becker MM; van Doremalen N; Fischer R; Wang N; Corbett KS; Choe M; Mason RD; Van Galen JG; Zhou T; Saunders KO; Tatti KM; Haynes LM; Kwong PD; Modjarrad K; Kong WP; McLellan JS; Denison MR; Munster VJ; Mascola JR; Graham BS
    J Virol; 2018 May; 92(10):. PubMed ID: 29514901
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Development of human monoclonal antibodies against diseases caused by emerging and biodefense-related viruses.
    Zhu Z; Dimitrov AS; Chakraborti S; Dimitrova D; Xiao X; Broder CC; Dimitrov DS
    Expert Rev Anti Infect Ther; 2006 Feb; 4(1):57-66. PubMed ID: 16441209
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The growth and potential of human antiviral monoclonal antibody therapeutics.
    Marasco WA; Sui J
    Nat Biotechnol; 2007 Dec; 25(12):1421-34. PubMed ID: 18066039
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Broadly Reactive Human Monoclonal Antibodies Elicited following Pandemic H1N1 Influenza Virus Exposure Protect Mice against Highly Pathogenic H5N1 Challenge.
    Nachbagauer R; Shore D; Yang H; Johnson SK; Gabbard JD; Tompkins SM; Wrammert J; Wilson PC; Stevens J; Ahmed R; Krammer F; Ellebedy AH
    J Virol; 2018 Aug; 92(16):. PubMed ID: 29899095
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Molecular Basis of a Protective/Neutralizing Monoclonal Antibody Targeting Envelope Proteins of both Tick-Borne Encephalitis Virus and Louping Ill Virus.
    Yang X; Qi J; Peng R; Dai L; Gould EA; Gao GF; Tien P
    J Virol; 2019 Apr; 93(8):. PubMed ID: 30760569
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pan-ebolavirus and Pan-filovirus Mouse Monoclonal Antibodies: Protection against Ebola and Sudan Viruses.
    Holtsberg FW; Shulenin S; Vu H; Howell KA; Patel SJ; Gunn B; Karim M; Lai JR; Frei JC; Nyakatura EK; Zeitlin L; Douglas R; Fusco ML; Froude JW; Saphire EO; Herbert AS; Wirchnianski AS; Lear-Rooney CM; Alter G; Dye JM; Glass PJ; Warfield KL; Aman MJ
    J Virol; 2016 Jan; 90(1):266-78. PubMed ID: 26468533
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Improving neutralization potency and breadth by combining broadly reactive HIV-1 antibodies targeting major neutralization epitopes.
    Kong R; Louder MK; Wagh K; Bailer RT; deCamp A; Greene K; Gao H; Taft JD; Gazumyan A; Liu C; Nussenzweig MC; Korber B; Montefiori DC; Mascola JR
    J Virol; 2015 Mar; 89(5):2659-71. PubMed ID: 25520506
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An anti-H5N1 influenza virus FcDART antibody is a highly efficacious therapeutic agent and prophylactic against H5N1 influenza virus infection.
    Zanin M; Keck ZY; Rainey GJ; Lam CY; Boon AC; Rubrum A; Darnell D; Wong SS; Griffin Y; Xia J; Webster RG; Webby R; Johnson S; Foung S
    J Virol; 2015 Apr; 89(8):4549-61. PubMed ID: 25673719
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Measles Virus Hemagglutinin epitopes immunogenic in natural infection and vaccination are targeted by broad or genotype-specific neutralizing monoclonal antibodies.
    Muñoz-Alía MA; Casasnovas JM; Celma ML; Carabaña J; Liton PB; Fernandez-Muñoz R
    Virus Res; 2017 May; 236():30-43. PubMed ID: 28465158
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Differences in the ease with which mutant viruses escape from human monoclonal antibodies against the HA stem of influenza A virus.
    Yamayoshi S; Yasuhara A; Ito M; Uraki R; Kawaoka Y
    J Clin Virol; 2018 Nov; 108():105-111. PubMed ID: 30292135
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Human Memory B Cells Producing Potent Cross-Neutralizing Antibodies against Human Parechovirus: Implications for Prevalence, Treatment, and Diagnosis.
    Westerhuis BM; Benschop KS; Koen G; Claassen YB; Wagner K; Bakker AQ; Wolthers KC; Beaumont T
    J Virol; 2015 Aug; 89(15):7457-64. PubMed ID: 25948742
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Isolation of Neutralizing Monoclonal Antibodies to Human Astrovirus and Characterization of Virus Variants That Escape Neutralization.
    Espinosa R; López T; Bogdanoff WA; Espinoza MA; López S; DuBois RM; Arias CF
    J Virol; 2019 Jan; 93(2):. PubMed ID: 30355681
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Human monoclonal antibodies that neutralize vaccine and wild-type poliovirus strains.
    Puligedda RD; Kouiavskaia D; Adekar SP; Sharma R; Devi Kattala C; Rezapkin G; Bidzhieva B; Dessain SK; Chumakov K
    Antiviral Res; 2014 Aug; 108():36-43. PubMed ID: 24824031
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mapping the Human Memory B Cell and Serum Neutralizing Antibody Responses to Dengue Virus Serotype 4 Infection and Vaccination.
    Nivarthi UK; Kose N; Sapparapu G; Widman D; Gallichotte E; Pfaff JM; Doranz BJ; Weiskopf D; Sette A; Durbin AP; Whitehead SS; Baric R; Crowe JE; de Silva AM
    J Virol; 2017 Mar; 91(5):. PubMed ID: 28031369
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Recombinant Receptor-Binding Domains of Multiple Middle East Respiratory Syndrome Coronaviruses (MERS-CoVs) Induce Cross-Neutralizing Antibodies against Divergent Human and Camel MERS-CoVs and Antibody Escape Mutants.
    Tai W; Wang Y; Fett CA; Zhao G; Li F; Perlman S; Jiang S; Zhou Y; Du L
    J Virol; 2017 Jan; 91(1):. PubMed ID: 27795425
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification of four distinct neutralizing epitopes on bluetongue virus serotype 10 using neutralizing monoclonal antibodies and neutralization-escape variants.
    Heidner HW; Rossitto PV; MacLachlan NJ
    Virology; 1990 Jun; 176(2):658-61. PubMed ID: 1693250
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Characterization of human monoclonal antibodies that neutralize multiple poliovirus serotypes.
    Puligedda RD; Kouiavskaia D; Al-Saleem FH; Kattala CD; Nabi U; Yaqoob H; Bhagavathula VS; Sharma R; Chumakov K; Dessain SK
    Vaccine; 2017 Oct; 35(41):5455-5462. PubMed ID: 28343771
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Development and Characterization of Neutralizing Antibodies Against Zaire Ebolavirus Glycoprotein and Protein 40.
    Yu DS; Weng TH; Shen L; Wu XX; Hu CY; Wang FXC; Wu ZG; Wu HB; Wu NP; Li LJ; Yao H
    Cell Physiol Biochem; 2018; 50(3):1055-1067. PubMed ID: 30355918
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.